We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential.
- Authors
Min Sun; Jilei Sun; Wei Sun; Xiaonan Li; Zhe Wang; Liwei Sun; Yuehui Wang
- Abstract
Cancer and diabetes are significant diseases that pose a threat to human health. Their interconnection is complex, particularly when they coexist, often necessitating multiple therapeutic approaches to attain remission. Sodiumglucose cotransporter protein two inhibitors (SGLT-2i) emerged as a treatment for hyperglycemia, but subsequently exhibited noteworthy extraglycemic properties, such as being registered for the treatment of heart failure and chronic kidney disease, especially with co-existing albuminuria, prompting its assessment as a potential treatment for various non-metabolic diseases. Considering its overall tolerability and established use in diabetes management, SGLT-2i may be a promising candidate for cancer therapy and as a supplementary component to conventional treatments. This narrative review aimed to examine the potential roles and mechanisms of SGLT-2i in the management of diverse types of cancer. Future investigations should focus on elucidating the antitumor efficacy of individual SGLT-2i in different cancer types and exploring the underlying mechanisms. Additionally, clinical trials to evaluate the safety and feasibility of incorporating SGLT-2i into the treatment regimen of specific cancer patients and determining appropriate dosage combinations with established antitumor agents would be of significant interest.
- Subjects
ANTINEOPLASTIC agents; CHRONIC kidney failure; HYPERGLYCEMIA; SODIUM-glucose cotransporters; SODIUM-glucose cotransporter 2 inhibitors; THERAPEUTICS; CANCER treatment
- Publication
Frontiers in Pharmacology, 2024, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2024.1369352